×
Hero Background

Nystagmus Companies

ID: MRFR/Pharma/3995-HCR
200 Pages
Rahul Gotadki
October 2025

Nystagmus is a condition characterized by involuntary, rhythmic eye movements that can occur horizontally, vertically, or in a rotary manner. Companies involved in the field of nystagmus may focus on various aspects, including diagnostics, treatments, and supportive technologies.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Nystagmus Market Research Report–Forecast till 2035 Infographic
Summary Table of Contents Segmentation Download PDF

Top Industry Leaders in the Nystagmus Market

Nystagmus Key Companies

 

Latest Nystagmus Companies Update


iOnctura Received FDA clearance for an investigational new drug application (IND) to study roginolisib in a Phase I clinical trial for uveal melanoma. This opens up potential for a new targeted therapy option.


Delcath Systems Received FDA approval for the HEPZATO Kit, which uses hepatic delivery of melphalan to treat metastatic ocular melanoma that has spread to the liver.


Agensys Conducted a Phase II study on pegilatinated interferon alpha-2b (PEG-IFN) for the treatment of uveal melanoma showing positive results in terms of progression-free survival. Further trials are planned.


Alnylam Pharmaceuticals Ongoing Phase 3 ENVISION2 study of givosiran for primary prevention of hepatic-associated complications in patients with non-syndromic ocular melanoma with GNAQ and GNA11 mutations.


List of Nystagmus Key Companies in the Market



  • Bristol-Myers Squibb Company

  • NUSAPURE

  • ALLERGAN

  • Aerie Pharmaceuticals Inc.

  • Pfizer Inc.

  • Valeant Pharmaceuticals International Inc.

  • Bayer AG

  • Genentech Inc.

  • Novartis AG

  • Regeneron Pharmaceuticals Inc.

  • Shire

  • and Santen Pharmaceutical Co. Ltd.